CEFTRIAXONE VIATRIS ceftriaxone (as sodium) 2 g powder for injection vial Australie - anglais - Department of Health (Therapeutic Goods Administration)

ceftriaxone viatris ceftriaxone (as sodium) 2 g powder for injection vial

alphapharm pty ltd - ceftriaxone sodium, quantity: 2386 mg (equivalent: ceftriaxone, qty 2000 mg) - injection, powder for - excipient ingredients: - ceftriaxone viatris is indicated for the treatment of the following infections when caused by susceptible aerobic organisms: lower respiratory tract infections caused by s. pneumoniae, streptococcus species (excluding enterococci), methicillin sensitive s. aureus, h. influenzae, h. parainfluenzae, klebsiella species (including k. pneumoniae), e. coli, e. aerogenes, proteus mirabilis and serratia marcescens. skin and skin structure infections caused by methicillin sensitive s. aureus, methicillin sensitive s. epidermidis, streptococcus group b, streptococcus group g, streptococcus pyogenes, streptococcus viridans, streptococcus species (excluding enterococci), peptostreptococcus species, e. coli, e. cloacae, klebsiella species (including k. pneumoniae, k. oxytoca), proteus mirabilis, morganella morganii, serratia marcescens. urinary tract infections (complicated and uncomplicated) caused by e. coli, proteus mirabilis, proteus vulgaris, m. morganii and klebsiella species (including k. pneumoniae). uncomplicated gonorrhoea (cervical/urethral and rectal) caused by neisseria gonorrhoea, including both penicillinase and non penicillinase producing strains. bacterial septicemia caused by s. pneumoniae, e. coli and h. influenzae. . bone infections caused by methicillin sensitive s. aureus, methicillin sensitive s. epidermidis, streptococcus group b, s. pneumoniae, streptococcus species (excluding enterococci), e. coli, enterobacter species, p. mirabilis and k. pneumoniae. joint infections caused by methicillin sensitive s. aureus, s. pneumoniae, streptococcus species (excluding enterococci), e. coli, p. mirabilis, k. pneumoniae and enterobacter species. meningitis: the initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by haemophilus influenzae type b, neisseria meningitidis, streptococcus pneumoniae or enterobacteriaceae pending culture and sensitivity results. surgical prophylaxis: the preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of post-operative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated and patients undergoing coronary artery bypass surgery. although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted. . susceptibility testing: before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing.

Pacific Ceftriaxone Sodium for Injection Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pacific ceftriaxone sodium for injection

viatris limited - ceftriaxone sodium 1193mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd);  ;   - powder for injection - 1000 mg - active: ceftriaxone sodium 1193mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)    

Pacific Ceftriaxone Sodium for Injection Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

pacific ceftriaxone sodium for injection

viatris limited - ceftriaxone sodium 2386mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd);  ;   - powder for injection - 2000 mg - active: ceftriaxone sodium 2386mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)    

Ceftriaxone (Devatis) Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

ceftriaxone (devatis)

devatis limited - ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - powder for infusion - 2 g - active: ceftriaxone sodium 2.386 g equivalent to ceftriaxone 2g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

Ceftriaxone (Devatis) Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

ceftriaxone (devatis)

devatis limited - ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - powder for injection - 0.5 g - active: ceftriaxone sodium 0.596 g equivalent to ceftriaxone 0.5g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

Ceftriaxone (Devatis) Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

ceftriaxone (devatis)

devatis limited - ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - powder for injection - 1 g - active: ceftriaxone sodium 1.193 g equivalent to ceftriaxone 1.0 g - infections caused by pathogens sensitive to ceftriaxone, e.g.: - sepsis - meningitis - abdominal infections (peritonitis, infections of the biliary and gastrointestinal tracts) - infections of the bones, joints, soft tissue, skin and of wounds; - infections in patients with impaired defence mechanisms - renal and urinary tract infections - respiratory tract infections, particularly pneumonia, and ear, nose and throat infections - genital infections, including gonorrhoea - perioperative prophylaxis of infections.

CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION Canada - anglais - Health Canada

ceftriaxone sodium for injection bp powder for solution

sterimax inc - ceftriaxone (ceftriaxone sodium) - powder for solution - 250mg - ceftriaxone (ceftriaxone sodium) 250mg - third generation cephalosporins

CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION Canada - anglais - Health Canada

ceftriaxone sodium for injection bp powder for solution

sterimax inc - ceftriaxone (ceftriaxone sodium) - powder for solution - 500mg - ceftriaxone (ceftriaxone sodium) 500mg - third generation cephalosporins

CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION Canada - anglais - Health Canada

ceftriaxone sodium for injection bp powder for solution

sterimax inc - ceftriaxone (ceftriaxone sodium) - powder for solution - 1g - ceftriaxone (ceftriaxone sodium) 1g - third generation cephalosporins

CEFTRIAXONE SODIUM FOR INJECTION BP POWDER FOR SOLUTION Canada - anglais - Health Canada

ceftriaxone sodium for injection bp powder for solution

sterimax inc - ceftriaxone (ceftriaxone sodium) - powder for solution - 2g - ceftriaxone (ceftriaxone sodium) 2g - third generation cephalosporins